National Health Investors earnings and dividend move

National Health Investors (NHI) recently reported second quarter 2026 results alongside an updated dividend. The company reported higher revenue and net income and announced a small increase to its quarterly cash dividend, raising it to $0.94 per share.

At a share price of US$73.24, National Health Investors has seen its 7 day share price return rise 4.7%, although the 30 day share price return is down 8%. The 1 year total shareholder return of 0.82% contrasts with a 3 year total shareholder return of 72.11%, which suggests that earlier momentum has cooled more recently.

If this earnings and dividend update has you reviewing income ideas, it could be a good moment to broaden your watchlist with 11 dividend fortresses

National Health Investors has had a strong run over three years but a much flatter past year and a mixed recent share price move. Is most of the easy upside already behind the stock, or does valuation still point to more ahead?

Most Popular Narrative: 14.6% Undervalued

On the most followed narrative, National Health Investors is priced below an implied fair value of $85.75, compared with the latest close at $73.24. This sets up a valuation story grounded in long term cash flows and sector demand.

Accelerating growth in the 75+ U.S. population and increased demand for senior housing are associated with higher occupancy rates and pricing power in NHI's SHOP portfolio, as reflected in recent quarter-over-quarter rises in both occupancy and RevPOR. This is cited in support of sustained revenue and net operating income (NOI) growth.

Want to see what sits behind that fair value for National Health Investors? The narrative focuses on multi year revenue expansion, steady margins and a richer earnings multiple than today. Curious which assumptions really move the model?

Result: Fair Value of $85.75 (UNDERVALUED)

However, the National Health Investors story also depends on SHOP occupancy stabilising and key tenants staying healthy, since weaker trends here could quickly challenge that undervalued case.

Another View on National Health Investors Valuation

There is a twist when looking at National Health Investors through its P/E ratio. The stock trades on 21.6x earnings, which is higher than the Global Health Care REITs average of 17.2x, yet still below an estimated fair ratio of 28.3x that the market could move toward. That mix of richer pricing than the sector, but a discount to the fair ratio and to a 64.4x peer average, points to real valuation risk if expectations fade, but also room for upside if earnings hold up. Which side of that trade off appears more likely to you?

Next Steps

Given the mix of optimism and concern around National Health Investors, it makes sense to review the full picture yourself and move quickly while sentiment is still mixed. To see both sides laid out clearly, start with these 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond National Health Investors?

If you want a broader set of options alongside National Health Investors, use the Simply Wall St screener to quickly surface stocks that fit your own checklist.

• Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations using 50 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with strong finances and robust balance sheets through the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for underfollowed opportunities that may not yet be widely discussed by filtering through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.